GSK and AZ 2Q26 progress further validates China's innovative drug assets going global

Overview

This report analyzes the read-through impact of GSK's and AstraZeneca's 2Q26 results and pipeline updates on Chinese healthcare companies Hansoh, Hengrui and Kelun Biotech. The core conclusion is that multinational pharmaceutical companies are not only continuing to license China's innovative drug assets, but are also investing late-stage clinical resources to maximize their global commercialization value.

Core views

The report is broadly positive on all three companies. For Hansoh, GSK plans to initiate multiple Ph3 studies for the B7-H3 ADC Ris-Rez and B7-H4 ADC Mo-Rez, and expects to submit a BLA for Ris-Rez in second-line small-cell lung cancer in 2028, indicating increased internal confidence in the related programs. For Hengrui, GSK’283 has entered Ph3 studies in multiple respiratory disease indications, meaning that the asset has passed GSK's technical and commercial evaluation, improving the visibility of future milestones and tiered sales royalties. For Kelun Biotech, Dato-DXd remains an important global reference for TROP2 ADCs, but the report believes that based on existing clinical data, it poses limited threat to sac-TMT in NSCLC, while sac-TMT's global Ph3 footprint and regulatory progress continue to strengthen its competitive position.

Analysis framework

The report uses a multinational pharmaceutical pipeline-event read-through approach, mapping the clinical stages, regulatory timelines, indication advancement and capital allocation priorities disclosed by GSK and AstraZeneca to the platform value, milestone revenue, competitive landscape and commercialization potential of Chinese licensors or comparable asset companies.

Methodology notes

• Event-driven researchEarnings and pipeline read-through

  Assessing the valuation implications for relevant China-licensed assets and comparable companies through quarterly earnings and R&D pipeline updates from multinational pharmaceutical companies.

  GSK's and AZ's Ph3 initiations, achievement of OS endpoints, BLA timelines and global clinical footprint are viewed as external validation of the quality of China's innovative drugs, late-stage development certainty and commercialization potential.

• Pharmaceutical R&D analysisClinical catalyst and regulatory pathway assessment

  Tracking milestones including Ph3 readouts, BLA submissions, priority reviews and indication expansions.

  The report focuses on key readouts and regulatory progress for multiple ADC and antibody programs during 2026-2028, and uses them to assess investment catalysts.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Hansoh Pharma - H (3692.HK)

  GSK licensed in Ris-Rez and Mo-Rez; the 2Q26 update shows progress on multiple Ph3 plans.

  Strengths

  GSK's acceleration of late-stage R&D investment, positive Ph3 data for Ris-Rez in SCLC and osteosarcoma, and further validation of the ADC platform's commercialization value.

  Weaknesses

  Value realization remains dependent on subsequent Ph3 success, BLA submission and global commercialization execution.

  Comparison

  Compared with assets that remain only at the licensing transaction stage, GSK's explicit late-stage trial plans indicate higher strategic priority.

  Risks

  Clinical failure, safety issues, slower-than-expected indication expansion or reallocation of GSK resources.

• Hengrui - H (1276.HK)

  GSK’283, a long-acting anti-TSLP antibody, originally came from Hengrui and entered the GSK system through the Aiolos Bio licensing pathway.

  Strengths

  GSK's decision to initiate Ph3 studies in asthma, COPD and CRSwNP indicates that the asset has passed internal technical and commercial evaluation; Hengrui can receive more than US$1 billion in milestones plus tiered sales royalties.

  Weaknesses

  Near-term revenue contribution remains dependent on milestone triggers and clinical progress.

  Comparison

  After entering registrational studies, execution certainty is higher than that of earlier-stage licensed assets.

  Risks

  Competition in respiratory disease indications, failure to meet expectations for Ph3 efficacy or safety, and delays in milestone realization.

• Kelun Biotech (6990.HK)

  Its sac-TMT competes with and serves as a reference for global TROP2 ADC programs including Dato-DXd.

  Strengths

  The collaboration with MSD has established a broad global development program with 17 global Ph3 studies; success in the global Ph3 study in endometrial cancer, positive first-line NSCLC Ph3 results in China and priority review for first-line TNBC support its competitive position.

  Weaknesses

  Valuation and catalysts are highly sensitive to clinical readouts, regulatory pace and partner execution.

  Comparison

  Dato-DXd is an important benchmark for TROP2 ADCs, but the report believes that based on existing data, it poses limited competitive threat to sac-TMT in NSCLC.

  Risks

  Subsequent readouts for Dato-DXd or other TROP2 ADCs exceeding expectations, failure of sac-TMT global trials or slower commercialization progress.

Key data

• Hansoh Pharma - H rating/price/target price3692.HK; HK$33.52; OW; HK$45Price as of the close on 2026-07-29; target price from J.P. Morgan's historical recommendation table.
• Hengrui - H rating/price/target price1276.HK; HK$58.30; OW; HK$68Price as of the close on 2026-07-29; target price from the OW recommendation dated 2026-06-15.
• Kelun Biotech rating/price/target price6990.HK; HK$497.60; OW; HK$648Price as of the close on 2026-07-29; target price from the OW recommendation dated 2026-07-16.
• GSK late-stage trial plans related to HansohBy 2028, Ris-Rez may have 6 Ph3 studies and Mo-Rez may have 5 Ph3 studiesGSK plans to initiate multiple late-stage studies for the B7-H3 and B7-H4 ADC combinations.
• Hengrui potential economic interestsMore than US$1 billion in total milestone payments plus tiered sales royaltiesRelated to the subsequent development and commercialization of the long-acting anti-TSLP antibody GSK’283.
• Global development scale of Kelun Biotech's sac-TMT17 ongoing global Ph3 studiesCovering multiple tumor types and lines of therapy through the collaboration with MSD.

Impact & implications

These updates reinforce the trend of China's innovative drugs progressing from early-stage licensing to global late-stage development and regulatory realization. For Hansoh and Hengrui, increased late-stage investment by multinational pharmaceutical companies implies improved visibility into platform capabilities, asset quality and potential milestone revenue; for Kelun Biotech, sac-TMT's broad global development plan and positive clinical and regulatory progress to date support maintaining its competitive positioning in the TROP2 ADC field.

Risks

• Relevant Ph3 studies fail to meet their primary endpoints or produce unfavorable safety data.
• Delays in BLA submissions, regulatory reviews or indication expansion timelines.
• Multinational pharmaceutical companies readjust capital allocation and reduce the strategic priority of licensed assets.
• Intensifying competition in the ADC field, particularly against the TROP2, B7-H3, B7-H4 and CLDN18.2 targets.
• Milestone payments and sales royalties are realized more slowly than the market expects.
• J.P. Morgan has market-making, client, investment banking or potential investment banking compensation relationships with some covered companies; investors should make independent judgments in conjunction with the disclosures.

What to watch

• The number and indication scope of subsequent Ph3 initiations by GSK for Ris-Rez and Mo-Rez, as well as the pace of the 2028 BLA submission for second-line SCLC Ris-Rez.
• Enrollment, readouts and milestone triggers for GSK’283 registrational studies in asthma, COPD and CRSwNP.
• 2H26/1H27 readouts for AstraZeneca's Dato-DXd in Avanzar/TROPION-Lung07 and TROPION-Breast03/05, among other trials.
• Progress of Kelun Biotech's global sac-TMT Ph3 programs, MSD's execution and the outcome of China's priority review for first-line TNBC.
• Regulatory and commercialization progress following Sone-Ve's achievement of the OS endpoint in CLDN18.2-positive gastric cancer.